Competitor Landscape: Spondyloarthritis
Summary
"Competitor Landscape: Spondyloarthritis", briefings contain evaluations of ongoing development activities within the Spondyloarthritis (SpA) disease market, together with analysis of current & potential future product positioning.
Key Highlights from the report -
Competitor Landscape: Spondyloarthritis (SpA) report comprises four key sections.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted the Spondyloarthritis (SpA) landscape.
Landscape Updates -
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Appendix -
Scope
Reasons to Buy
Summary
"Competitor Landscape: Spondyloarthritis", briefings contain evaluations of ongoing development activities within the Spondyloarthritis (SpA) disease market, together with analysis of current & potential future product positioning.
Key Highlights from the report -
- Given that only 187 patients are currently enrolled in upadacitinib’s Phase II/III SELECT-Axis 1 trial in AS, it is assumed that AbbVie will need to run a Phase III program before filing.
- Secukinumab’s EU label update for PsA will bring it in-line with its US label, and is expected to become a key point of differentiation.
- Change in primary completion date of the Phase III COAST-X trial is not expected to influence ixekizumab’s regulatory timeline in any way, with Lilly stating that it expects to file for regulatory approval of ixekizumab in AS and nr-axSpA, simultaneously, by YE 2018.
Competitor Landscape: Spondyloarthritis (SpA) report comprises four key sections.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted the Spondyloarthritis (SpA) landscape.
Landscape Updates -
- ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
- Timeline forecasts for each approved product’s lifecycle management initiatives.
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies.
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Appendix -
- Current early-stage SpA pipeline & candidate ‘Watch List’.
- Timeline assumptions, including standard assumptions & drug-specific assumptions.
Scope
- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to Buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharma’s Spondyloarthritis (SpA) ‘Competitor Landscape’Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- AbGenomics
- Abivax
- Ablynx
- ACEA Biosciences
- Acerta Pharma
- Akari Therapeutics
- Akros Pharma
- Almirall
- Amgen
- Asana Biosciences
- Astellas
- AstraZeneca
- Bayer
- Biocad
- Bird Rock Bio
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Can-Fite Biopharma
- Celgene
- Chemo-Centryx
- Cyclacel
- Daichii Sankyo
- Eddingpharm
- Eisai
- Eli Lilly
- EMD Serono
- Ensemble Therapeutics
- Galapagos
- Genentech
- Gilead
- GSK
- Hanmi
- Hoffmann-La Roche
- Hutchison Medi Pharma
- Innate Pharma
- Innocare Pharma
- Istesso
- Izana Bioscience
- Janssen
- Japan Tobacco
- Jiangsu HengRui
- Kineta
- Kyowa Hakko Kirin
- Leo Pharma
- Lupin
- MacroGenics
- MedImmune
- Merck
- Merck KGaA
- Mesoblast
- Momenta
- MorphoSys
- Morphotek
- MSD
- Nektar Therapeutics
- Novartis
- NovImmune
- Noxopharm
- Nuevolution
- Oscotec
- OSE Immuno Therapeutics
- Pfizer
- Philogen
- Principia Biopharma
- Protalex
- Reata Pharmaceuticals
- Regen BioPharma
- Regeneron
- Rigel
- Rottapharm Biotech
- R-Pharm
- Sanofi
- Sareum
- Sun Pharma
- Swedish Orphan Biovitrum
- SynAct Pharma
- Taiho
- Taisho
- Takeda
- TiGenix
- UCB
- Valeant
- Viela Bio
- Vitae Pharmaceuticals
- Vitaeris
- WuXi
- Xencor
